

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0047

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	10/010,940
Filing Date	December 5, 2001
First Named Inventor	Jiangchun Xu
Group Art Unit	1631
Examiner Name	
Attorney Docket No.	210121.427D3

RECEIVED
JAN 14 2003
TECH CENTER 160012900

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO-1449 (7 sheets) <input checked="" type="checkbox"/> Cited References (4) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Additional Enclosure(s) (please identify below): _____ _____ _____
--	---	--

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	Jeffrey Hundley, Ph.D. 42,676	 00500 PATENT TRADEMARK OFFICE
Signature		
Date	January 10, 2003	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.

Typed or printed name	Lawrence Teague	
Signature		Date: January 10, 2003



RECEIVED
JAN 4 2003
PATENT
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Jiangchun Xu et al.
Application No. : 10/010,940
Filed : December 5, 2001
For : COMPOSITIONS AND METHODS FOR THE THERAPY AND
DIAGNOSIS OF PROSTATE CANCER

Art Unit : 1631
Docket No. : 210121.427D3

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449. This application is a divisional and relies, under 35 U.S.C. § 120, on the earlier filing date of prior application USAN 09/439,313, filed November 12, 1999; which is a continuation-in-part of USAN 09/352,616, filed July 13, 1999; which is a continuation-in-part of USAN 09/288,946, filed April 9, 1999; which is a continuation-in-part of USAN 09/232,149, filed January 15, 1999; which is a continuation-in-part of USAN 09/159,812, filed September 23, 1998; which is a continuation-in-part of USAN 09/115,453, filed July 14, 1998; which is a continuation-in-part of USAN 09/030,607, filed February 25, 1998; which is a continuation-in-part of USAN 09/020,956, filed February 9, 1998; which is a continuation-in-part of USAN 08/904,804, filed August 1, 1997; which is a continuation-in-part of USAN 08/806,099, filed February 25, 1997. The references listed on pages 1-6 of the attached Forms PTO-1449 were submitted to and/or cited by the Office in these prior applications and, therefore, are not required to be provided in the present application. If the Examiner wishes, copies will be provided upon request.

However, cited references GC-GF on page 7 of the attached Forms PTO-1449 were not submitted to and/or cited by the Patent and Trademark Office in the above-identified prior applications and copies are provided herewith.

#14/I.D.S.

Applicants note that reference AB is written in German. Accordingly, the Examiner's attention is respectfully directed to reference BN, which sets forth an English abstract of this reference.

Applicants note that reference AE is not written in English. Accordingly, the Examiner's attention is respectfully directed to the cover page, which sets forth an English language abstract.


Applicants note that reference BB is not written in English. Accordingly, the Examiner's attention is respectfully directed to the cover page, which sets forth an English language abstract.

Applicants' note that reference CB (WO 98/37039) is written in Japanese. Accordingly, the Examiner's attention is respectfully directed to the cover page which contains an English abstract.

As to any reference made of record on the attached Form PTO-1449, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC




Jeffrey Hundley, Ph.D.
Registration No. 42,676

JEH:ljt
Enclosures:
Postcard
PTO/SB/21
Form PTO-1449 (7 Sheets)
701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
(206) 622-4900
Fax: (206) 682-6031

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.427D3APPLICATION NO..
10/010,940 #14/

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS
Jiangchun Xu et al.FILING DATE
December 5, 2001GROUP ART UNIT
1631

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	5,786,148	07/28/98	Randman et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AB	DE 19649207	11/27/96	Germany		X
	AC	EP 317 141 A2	05/24/89	EPO		
	AD	EP 652 014 A1	5/10/95	EPO		
	AE	EP 936 270 A2	08/18/99	EPO		X
	AF	WO 93/14755	08/05/93	PCT		
	AG	WO 93/25224	12/23/93	PCT		
	AH	WO 94/09820	05/11/94	PCT		

RECEIVED
JAN 14 2003
TECH CENTER 1600/2900

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AI	Ahn and Kunkel, "The structural and functional diversity of dystrophin," <i>Nature Genetics</i> 3: 283-291, April, 1993.
AJ	Alexeyev et al., "Improved antibiotic-resistance gene cassettes and omega elements for <i>Escherichia coli</i> vector construction and in vitro deletion/insertion mutagenesis," <i>Gene</i> 160:63-67, 1995.
AK	Berthon et al., "Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43," <i>Am. J. Hum. Genet.</i> 62(6):1416-1424, June 1998.
AL	Blok et al., "Isolation of cDNA that are differentially expressed between androgen-dependent and androgen-independent prostate carcinoma cells using differential display PCR," <i>The Prostate</i> 26:213-224, 1995.
AM	Busselmakers et al., Genbank Accession No. AF103907, August 14, 2000.
AN	Busselmakers et al., Genbank Accession No. AF103908, August 14, 2000.
AO	Cawthon et al., "cDNA sequence and genomic structure of EVI2B, a gene lying within an intron of the neurofibromatosis type 1 gene," <i>Genomics</i> 9:446-460, 1991.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

INFORMATION DISCLOSURE STATEMENT

(Use separate sheets if necessary)

APPLICANTS
Jiangchun Xu et al.FILING DATE
December 5, 2001GROUP ART UNIT
1631

U.S. PATENT DOCUMENTS

*EXAMINER
INITIAL

DOCUMENT NUMBER

DATE

NAME

CLASS

SUBCLASS

FILING DATE
IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BA	WO 95/04548	02/16/95	PCT		
	BB	WO 95/14772	06/01/95	PCT (Cover page with English abstract only)		X
	BC	WO 95/30758	11/16/95	PCT		
	BD	WO 96/21671	07/18/96	PCT		
	BE	WO 97/33909	09/18/97	PCT		
	BF	WO 98/12302	03/26/98	PCT		
	BG	WO 98/17687	04/30/98	PCT		
	BH	WO 98/20117	05/14/98	PCT		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BI	Chu et al., "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity," <i>J. Exp. Med.</i> 186(10): 1623-1631, November 17, 1997.
	BJ	Coleman et al., <i>Fundamental Immunology</i> , Wm. C. Brown Publishers, Dubuque, Iowa, 1989, pp. 465-466.
	BK	Database EMBL Accession No. AA453562, June 11, 1997, Hillier et al., "Homo sapiens cDNA clone 788180."
	BL	Derwent Geneseq Database, Accession No. V58522, December 8, 1998.
	BM	Derwent Geneseq Database, Accession No. V61287, January 6, 1999.
	BN	Duerst and Nees, "Nucleic acid characteristic of late or early passage cells immortalized by papilloma virus-and related polypeptide(s) and antibodies, used for diagnosis and treatment of cervical cancer and assessing potential for progression of cervical lesions," Derwent World Patent Index, Accession No. 1998-121623, 1998. See also German Patent DE 19649207 C1.
	BO	El-Shirbiny, "Prostatic Specific Antigen, <i>Advances In Clinical Chemistry</i> 31:99-133, 1994.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

Sheet 3 of 4
RECEIVED
 JAN 14 2003
 TECH CENTER 1900/2900

FORM PTO-1449
 (REV.7-80)

U.S. DEPARTMENT OF COMMERCE
 PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
 210121.427D3

APPLICATION NO.
 10/010,940


INFORMATION DISCLOSURE STATEMENT

(See several sheets if necessary)

APPLICANTS
 Jiangchun Xu et al.

FILING DATE
 December 5, 2001

GROUP ART UNIT
 1631



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOC. #	DOC. NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	--------	-------------	------	------	-------	----------	-------------------------------

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	CA	WO 98/31799	07/23/98	PCT		
	CB	WO 98/37039	08/27/98	PCT		X
	CC	WO 98/37093	08/27/98	PCT		
	CD	WO 98/37418	08/27/98	PCT		
	CE	WO 98/38310	09/03/98	PCT		
	CF	WO 98/39446	09/11/98	PCT		
	CG	WO 98/45435	10/15/98	PCT		
	CH	WO 98/50567	11/12/98	PCT		
	CI	Ezzell, C., "Cancer vaccines: an idea whose time has come?" <i>The Journal of NIH Research</i> 7:46-49, January, 1995.				
	CJ	GenBank Accession Number AF047020, February 1, 1999.				
	CK	Hara et al., "Characterization of cell phenotype by a novel cDNA library subtraction system: expression of CD8 α in a mast cell-derived interleukin-4-dependent cell line," <i>Blood</i> 84(1):189-199, July 1, 1994.				
	CL	Harris et al., "Polycystic Kidney Disease 1: identification and analysis of the primary defect," <i>J. Am. Soc. of Nephrol.</i> 6:1125-1133, 1995.				
	CM	Hillier et al., Genbank Accession No. AA100799, December 23, 1997.				
	CN	Hillier et al., Genbank Accession No. R20590, April 18, 1995.				
	CO	Hudson, T., Genbank Accession No. G22461, May 31, 1996.				

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
210121.427D3

APPLICATION NO..
10/010,940

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

APPLICANTS
Jiangchun Xu et al.

FILING DATE
December 5, 2001

GROUP ART UNIT
1631

Sheet 4 of 4
JAN 14 2003
TECH CENTER 1600/2800
RECEIVED

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
----------------------	-----------------	------	------	-------	----------	-------------------------------

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	DA	WO 99/06548	02/11/99	PCT		
	DB	WO 99/06552	02/11/99	PCT		
	DC	WO 99/06550	02/11/99	PCT		
	DD	WO 99/25825	05/27/99	PCT		
	DE	WO 99/31236	06/24/99	PCT		
	DF					
	DG					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	DH	Kroger, B. "New serine protease form human prostate, useful for identifying specific inhibitors, antibodies and probes," Derwent World Patent Index, Accession No. 99-432218, 1999. See also European Patent EP 936 270 A2.
	DI	Lalvani et al., "Rapid effector function in CD8 ⁺ memory cells," <i>J. Exp. Med.</i> 186(6):859-865, September 15, 1997.
	DJ	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551449, September 5, 1997.
	DK	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551759, August 11, 1997.
	DL	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA631143, October 31, 1997.
	DM	National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA653016, November 25, 1997.
	DN	Nelson et al., Genbank Accession No. NP_004908, March 18, 2000.

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS
Jiangchun Xu et al.FILING DATE
December 5, 2001GROUP ART UNIT
1631

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
EA						
EB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
EC						
ED						
EE						

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EF	Robson et al., "Identification of prostatic adrogen regulated genes using the differential display technique," <i>Proceeding of the American Association for Cancer Research Meeting</i> 86, 36: p.266, Abstract No. 1589, 1995.
EG	Schena et al., "Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes," <i>Proc. Natl. Acad. Sci. USA</i> 93(19):10614-10619, September 17, 1996.
EH	Schmidt-Wolf et al., "Activated T cells and cytokine-induced CD3 ⁺ CD56 ⁺ killer cells," <i>Annals of Hematology</i> 74:51-56, 1997.
EI	Sherman et al., "Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8," <i>Science</i> 258(5083):815-818, October 30, 1992.
EJ	Short et al., "λ ZAP: a bacteriophage λ expression vector with <i>in vivo</i> excision properties," <i>Nucleic Acids Research</i> 16(15):7583-7600, 1988.
EK	Sjögren, H., "Therapeutic Immunization Against Cancer Antigens Using Genetically Engineered Cells," <i>Immunotechnology</i> 3: 161-172, 1997.
EL	Smith et al., "Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search," <i>Science</i> 274(5291), 1371-1374, November 22, 1996.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Jiangchun Xu et al.

FILING DATE

December 5, 2001

GROUP ART UNIT

1631

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FA						
FB						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
FC					
FD					
FE					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

FF	Theobald, et al., "Targeting p53 as a general tumor antigen," <i>Proc. Natl. Sci. USA</i> 92(25):11993-11997, December 5, 1995.
FG	Tusnady and Simon, "Principles governing amino acid compositions of integral membrane proteins: application to topology prediction," <i>J. Mol. Biol.</i> 283(2):489-506, October 23, 1998.
FH	Van Tsai et al., "In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells," <i>Critical Reviews in Immunology</i> 18:65-75, 1998.
FI	Vasmatzis et al., "Discovery of three genes specifically expressed in human prostate by expressed sequence tag database analysis," <i>Proc. Natl. Acad. Sci. USA</i> 95(1):300-304, January 6, 1998.
FJ	Yee et al., "Isolation of tyrosinase-specific CD8 ⁺ and CD4 ⁺ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus," <i>The Journal of Immunology</i> 157(9):4079-4086, November 1, 1996.
FK	Zitvogel et al., "Eradication of Established Murine Tumors Using a Novel Cell-Free Vaccine: Dendritic Cell-Derived Exosomes," <i>Nature Medicine</i> 4(5): 594-600, May, 1998.
FL	
FM	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.427D3APPLICATION NO.
10/010,940

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS
Jiangchun Xu et al.FILING DATE
December 5, 2001GROUP ART UNIT
1631

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	GA						
	GB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	GC	WO 00/04149	1/27/00	WIPO		
	GD	WO 01/25272	4/12/01	WIPO		
	GE	WO 01/34802	5/17/01	WIPO		
	GF	WO 01/51633	7/19/01	WIPO		
	GG					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	GH		
	GI		
	GK		
	GL		
	GM		
	GN		
	GO		

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

RECEIVED
JAN 14 2003
TECH CENTER 1600/12900